3D printing will be a $32bn industry by 2025, rising to over $60bn by 2030, according to estimates from analytics firm GlobalData. The CAGR between 2018 and 2025 will be 16%, with software growing slightly faster than hardware, materials and services.
How much healthcare will contribute to this growth remains to be seen. In 2018, healthcare represented only 10% of online printing demand. In contrast, the industrial and electrical sectors represented approximately 50%.
But changing trends may see a necessity for more 3D printing in hospitals and places of care. As a new GlobalData report on 3D printing in healthcare states, the growing old-age population has driven the demand for donor organs, while regenerative medicine using bioprinted, patient-derived stem cells allows for personalised treatment of certain diseases.
Use of bioprinted human tissue in drug discovery allows for quicker and more efficient processes, with better outcomes compared to using animal tissue, say the researchers. It also removes the need for animal testing, both in drug and cosmetic development.
3D printing may also revolutionise Big Pharma, with drugs being printed and adapted to specific patient requirements such as age and weight. This could equally save the pharmaceutical industry millions in costs, resources and waste.
It shouldnt be a surprise to know that the pandemic has played its part in galvanising the technologys use. The 3D printing community, from major manufacturers to start-ups and individuals, has responded to the Covid crisis by pledging to support the production of vital medical equipment such as ventilators and personal protective equipment (PPE) for hospitals tackling the pandemic.
A recent study into the costs versus benefits of introducing 3D printing technology into hospitals has shown that the tech can aid complicated surgeries.
The June study, undertaken by Dr Atanu Chaudhuri, Associate Professor in Technology and Operations Management at Durham University Business School, alongside colleagues at ORT Braude College of Engineering in Israel and the University of Southern Denmark, assessed the effectiveness of 3D printing technologies used in hospitals.
Results show 3D printing to be a key tool in easing both time and financial pressures for hospitals.
Surgeries with durations of 4-8 hours can be shortened by 1.5-2.5 hours if patient specific instruments are used and 25-30 minutes shorter if only an anatomical model is used to plan the surgery, Dr Chaudhuri tells Verdict.
Patient recovery times are also shorter (e.g. a patient is able to walk 1-2 days after surgery compared to 3-4 days before). Moreover, the patient will avoid any post-surgical complications and hence will not need to visit hospital or undergo other kinds of treatment.
Chaudhuri doesnt specifically compare success rates, noting that even earlier surgeries had been successful but could have led to post-surgical complications and longer recover time.
But, there are certain surgeries which were not attempted before, especially for smaller children, which could now be conducted with much more confidence, he reveals.
Whilst the benefits are clear and compelling, Chaudhuri and his fellow researchers advise caution. They acknowledge that 3D printing is a significant financial investment for hospitals to make, particularly those run by the British NHS already operating under heavy financial pressures, especially in pandemic times.
Benefits can far outweigh costs both for hospitals as well as for patients, says Chaudhuri. But, we must know where to apply it and how to quantify the benefits.
He also believes 3D printing should be a collaboration between surgeons and engineers, with no one party having an advantage over another through clinical or technical knowledge.
(One) myth is that Surgeons should not be involved in design or 3D printing. But surgeons who are learning how to do segmentation, how to design a surgical guide, will be ahead of others. Eventually many surgeons will like to learn about 3D printing and it will get integrated with the medical curriculum.
The other myth is Engineers from service providers do not understand clinical requirements well.
This may be initially true but many service providers have learnt the clinical aspects by working with many surgeons and hence when they talk to a hospital, which has not applied the technology before, they will already provide valuable experience and guidance, particularly on what is possible and what is not.
Clinical and operational outcomes of using 3D printing in surgeries have been demonstrated. But Chaudhuri sees a need for systematic studies for which type of surgeries and for which patient characteristics, are the impacts highest?
For public health systems, such cost-benefits analysis is critical, he tells Verdict. For private healthcare, there should be value-for-money for patients.
Chaudhuri says use of anatomical models will become standard for surgeries. 3D printed surgical guides and implants meanwhile will be used where the benefits are highest followed by advanced 3D printed models for surgical simulations for more complex surgeries.
3D bio printing i.e. printing of organs is further out in the horizon, but development is happening at a rapid pace.
Use of virtual and augmented reality in combination with 3D printing has high potential for complex surgeries, which deal with challenges of high visual-spatial complexity and extensive anatomic variation.
The physician also predicts a strong demand for tailor-made medical implants and surgical instruments to individual patients.
One of the leading applications of 3D printing in surgeries are in orthopaedics and orthopaedic oncology, especially in complex restructuring operations, followed by cranio-maxillofacial, neurosurgeries and cardiology.
(But) as I said before, more studies are needed across specialties and for different types of patients.
The future of 3D printing in healthcare will rely on executives as much as acceptance from medical experts. According to the data, it looks as though management is taking note.
In GlobalDatas Emerging Technology Trends Survey 2019 report, 146 medical executives were surveyed across 23 countries. All respondents confirmed some level of engagement with new and emerging technologies.
According to respondents, three-quarters of medical device companies expected 3D printing to disrupt the sector. When asked when they think 3D printing will start having a disruptive influence on the sector, 62% of industry leaders believed the disruption would occur within the next two to three years.
A total of 67% of respondents indicated that their business was ready for the impact 3D printing may bring, while approximately one-third indicated their business is not. Most medical device companies are currently using 3D printing, with only 15% of respondents stating that they were not at all likely to use it within the next three years.
When asked about spending on 3D printing, most medical device companies expect to increase budgetary allocation to the technology over the next five years compared to current spending. This means that although some companies may harbour doubts over the nature of the disruption to come, they are still planning to increase investments into the trend.
Two-fifths of companies surveyed see issues with the visibility of return on investment (ROI) as one of the barriers to adopting 3D printing. Concerns for CapEx budget constraints, technology integration challenges, and lack of skills were also highlighted as barriers.
As ROI and lack of in-house skills are cause for concern for respondents, the majority of companies (67%) were foregoing developing in-house acumen for partnerships with established 3D printing technology providers.
When asked what business objectives these companies are seeking to accomplish from investments in 3D printing technology, most respondents expect to be rewarded by efficiency (53%) and innovation gains (49%).Related Report Download the full report from GlobalData's Report StoreGet the Report
Latest report from Visit GlobalData Store
Go here to read the rest:
- BioLineRx Announces Positive Results from Pharmacoeconomic Study Positioning Motixafortide as Potential Standard of Care in Stem Cell Mobilization -... - October 17th, 2021
- Misinformation on stem cell treatments for COVID-19 linked to overhyped science, researchers argue - EurekAlert - October 17th, 2021
- FDA Approves Genentech's Tecentriq as Adjuvant Treatment for Certain People With Early Non-Small Cell Lung Cancer - BioSpace - October 17th, 2021
- Nic Chapman: my MS battle and the treatment that's given me hope - The Times - October 17th, 2021
- Dream Body Clinic Stem Cell Therapy Stem Cells HGH - October 13th, 2021
- Hematopoietic Stem Cells - October 13th, 2021
- Top 10 Best Stem Cell Supplement Brands - Healthtrends - October 13th, 2021
- Mitochondrial superoxide dismutase overexpression and low oxygen conditioning hormesis improve the performance of irradiated sterile males |... - October 13th, 2021
- Researchers uncover how cancer cells use sugar residue to evade the immune system - News-Medical.net - October 13th, 2021
- The science and practicality of cultured meat The Stute - The Stute - October 11th, 2021
- Vitro Biopharma Inc. July 31st 2021; 3rd Quarter ended Financial Results of Operations and Shareholder Le - Benzinga - October 11th, 2021
- Want To Support Healthy Bones? It's Time To Get Your Vitamin D In Check - mindbodygreen.com - October 11th, 2021
- Joint : Why Breast Cancer Awareness Matters, and How to Get It Done - marketscreener.com - October 11th, 2021
- Faster healing of wounds can decrease pain and suffering and save lives - KY3 - October 7th, 2021
- Fasting boosts stem cells regenerative capacity | MIT ... - October 7th, 2021
- Adventist Review Online | Vaxed, Vexed, or Other? - Adventist Review - October 7th, 2021
- Sickle cell disease patients given hope for the future with first new treatment in 20 years - iNews - October 7th, 2021
- StemExpress Partners with the Alliance for Regenerative Medicine to Provide COVID-19 Testing for the Cell and Gene Meeting on the Mesa - WCAX - October 7th, 2021
- New Australian-first gene therapy gives Rylee and Saman sight at night and the chance at a new life - ABC News - October 7th, 2021
- Is Stathmin-2 the Next Piece of the ALS Jigsaw Puzzle? - BioSpace - October 7th, 2021
- Ashley Black, Entrepreneur Of The Year For Health And Beauty, To Launch Best-Selling FasciaBlaster System - LatestLY - October 5th, 2021
- 25 Best Body Scrubs and Exfoliators in 2021 - the Trend Spotter - The Trend Spotter - October 5th, 2021
- Potential of exosomes as cell-free therapy | IJN - Dove Medical Press - October 2nd, 2021
- Poseida Therapeutics to Present at Society for Immunotherapy of Cancer 2021 Annual Meeting - PRNewswire - October 2nd, 2021
- 12 of the best face serums 2021 - Medical News Today - October 2nd, 2021
- Humanigen Submits All Planned Modules for Potential Conditional Marketing Authorization from the UK's MHRA - Business Wire - October 2nd, 2021
- Envigo Announces Collaboration With Biocytogen to Distribute the B-NDG Triple Immunodeficient and Humanizable Mouse Model - StreetInsider.com - September 29th, 2021
- Large-Scale Bioproduction of Adherent Cells To Support Advanced Therapy Workflows - Technology Networks - September 29th, 2021
- Sidney author warns against the abuses of technology Saanich News - Saanich News - September 27th, 2021
- Jasper Therapeutics Closes Transaction With Amplitude Healthcare Acquisition Corporation, Creating a Publicly Traded Biotechnology Company Dedicated... - September 25th, 2021
- Dr. Sean Kelishadi provides stem cell therapy for facial procedures - Digital Journal - September 25th, 2021
- Pipeline of cell and gene therapies holds promise for repairing the Parkinsonian brain - EurekAlert - September 25th, 2021
- National Institutes of Health awards Children - EurekAlert - September 25th, 2021
- Amplitude Healthcare Acquisition : Announces Shareholder Approval of Business Combination with Jasper Therapeutics, Inc (Form 8-K) -... - September 25th, 2021
- Can you mix and match COVID vaccines or boosters? What scientists and doctors say - CNET - September 22nd, 2021
- All The Reasons Why You Should Add Nutrient-Dense Mushrooms To Your Diet - NDTV Doctor - September 22nd, 2021
- My children know I have a terminal illness talking openly about cancer benefits all of us - iNews - September 22nd, 2021
- Orthopedic Regenerative Surgical Products Market Size to Expand Significantly by the End of 2031 - BioSpace - September 22nd, 2021
- Health tips from Dr. Oz and Dr. Roizen for 9-21-21 - The Commercial Dispatch - September 22nd, 2021
- Prescription Drugs Can Be Affordable and Innovative - Center For American Progress - September 18th, 2021
- The Promise of Regenerative Medicine to Treat Chronic Pain - Mega Doctor News - September 18th, 2021
- Precise CRISPR gene editing can correct the mutation that causes cystic fibrosis in mini-intestines - Massive Science - September 18th, 2021
- Fate Therapeutics Announces Publication of FT538 Preclinical Data Demonstrating Enhanced ... - The Bakersfield Californian - September 18th, 2021
- A New Company With a Wild Mission: Bring Back the Woolly Mammoth - The New York Times - September 14th, 2021
- TreeFrog Therapeutics Secures $75m In Series B Financing To Advance A Pipeline Of Stem Cell-Derived Cell Therapies And Deploy Proprietary C-Stem... - September 14th, 2021
- Therapeutic inhibition of USP9x-mediated Notch signaling in triple-negative breast cancer - pnas.org - September 14th, 2021
- What are the health benefits of nectarines? - Medical News Today - September 10th, 2021
- Time to humanize European health research with an action plan - POLITICO.eu - September 10th, 2021
- Tiny radio tags reveal the lives of Neotropical stingless bees - Massive Science - September 10th, 2021
- Bristol Myers Squibb Research at ESMO 2021 Demonstrates Clinical Benefits of Immunotherapies in Multiple Hard-to-Treat Advanced or Metastatic Cancers... - September 8th, 2021
- Opdivo: Use with Yervoy, Side Effects, Cost, and More - Healthline - September 8th, 2021
- The Deal in Duluth: Catholics here on their own in seeking a religious exemption to being vaccinated - Duluth News Tribune - September 8th, 2021
- Diagnosis and Treatment of Three Primary Malignant Tumors | BCTT - Dove Medical Press - September 8th, 2021
- Jeff Bezos is reportedly funding Altos Labs, a new anti-ageing venture aiming to cheat death - Screen Shot - September 7th, 2021
- Sorrento Announces Enrollment of First Subject in Brazil Phase 2 Study of COVI-MSC for Treatment of COVID-19 Associated Acute Respiratory Distress in... - September 2nd, 2021
- 11 of the best vitamin C serums 2021 - Medical News Today - September 2nd, 2021
- Joint Committee on Vaccination and Immunisation (JCVI) advice on third primary dose vaccination - GOV.UK - September 2nd, 2021
- Japanese scientists have 3D printed a square of lab-grown wagyu beef - The A.V. Club - September 2nd, 2021
- This Company is Producing Bioprinted Fur, Wool & Eyelashes Which Could Make Fur Farms Obsolete - vegconomist - the vegan business magazine -... - September 2nd, 2021
- Poseida Therapeutics Presents Preliminary Results from Phase 1 Trial of P-PSMA-101 at the 6th Annual CAR- - Benzinga - September 1st, 2021
- Operational Highlights and Financial Results for the Year Ended June 30, 2021 - GlobeNewswire - September 1st, 2021
- KNUCKLES Role in Flower Clock; This Tiny Multi-Functional Protein Helps Complete Floral Development Properly at the Right Time - Science Times - September 1st, 2021
- Outlook on the Multiple Myeloma Drugs Global Market to 2026 - by Therapy, Drug Type, End-user, Distribution Channel and Region - Yahoo Finance - August 30th, 2021
- 6 Benefits of Not Eating Meat (or at Least Less of It) - Healthline - August 30th, 2021
- Cell Therapy Manufacturing Market by Type of Cell Manufactured, Source of Cell, Scale of Operation, Purpose of Manufacturing and Key Geographical... - August 25th, 2021
- The world's first 3D-printed Wagyu beef is revealed-it's marbling like the real thing - Texasnewstoday.com - August 25th, 2021
- Science-Backed Benefits of Prickly Pear Cactus - Healthline - August 25th, 2021
- AdAlta and Carina Biotech to develop next-generation CAR-T cancer therapeutics | More News | News Channels - PipelineReview.com - August 25th, 2021
- Educating California and the world on the benefits of hydrogen-powered transportation - H2 View - August 25th, 2021
- The Future is Fat: The Startups Looking to Fatten up Vegan Food - vegconomist - the vegan business magazine - August 25th, 2021
- This tech investor believes well soon live to 150. Here are his seven longevity hacks - The Irish Times - August 25th, 2021
- The Best New CBD Skincare Products Of 2021 (So Far) - Forbes - August 25th, 2021
- FDA Approval, Efficacy, Boosters and More: Which COVID Vaccine is Best for You? - NBC Chicago - August 25th, 2021
- Plant Stem Cell Market Technology Research and Global Outlook By Our Experts The Manomet Current - The Manomet Current - August 22nd, 2021
- AAPI's National Blood Donation Drive and Stem Cell Registry Launched, Honoring Fallen Covid Warriors The Indian Panorama - The Indian Panorama - August 22nd, 2021
- Stem Cells Facts and Quiz - WebMD - August 20th, 2021
- Stem cells | healthdirect - August 20th, 2021
- Research Study Published in Functional Foods Highlights Benefits of a Proprietary CBD Formula for Neurological Health - The Free Press Tampa - August 20th, 2021
- Leukemia Stem Cell Transplant: Benefits, Procedure, Side ... - August 20th, 2021
- Fate Therapeutics Announces Positive Interim Clinical Data from its FT596 and FT516 Off-the-shelf, iPSC - GlobeNewswire - August 20th, 2021